FMC reported second-quarter 2026 revenue of $867.1 million and a consolidated GAAP net loss of $186.3 million, or $1.49 per diluted share. Adjusted EBITDA for the quarter was $152.6 million and diluted adjusted after-tax earnings from continuing operations per share were $0.26. The company updated its full-year outlook, lowering revenue excluding India to $3.50–$3.70 billion and adjusted EBITDA to $620–$680 million.

Financial Highlights

  • Revenue: $867.1 million for Q2 2026 (down 17% versus Q2 2025).
  • Gross margin: $342.1 million (gross profit reported on consolidated statement).
  • Net income (loss): GAAP net loss of $186.3 million for Q2 2026; GAAP net loss attributable to FMC stockholders of $186.6 million.
  • Adjusted EBITDA (non-GAAP): $152.6 million for the three months ended June 30, 2026.
  • Adjusted diluted EPS (non-GAAP): $0.26 for Q2 2026; GAAP diluted loss per share $1.49.

Business Highlights

  • Revenue excluding India totaled $841.4 million for Q2 2026, a 20% decline versus prior year; organic revenue declined 22% when excluding foreign currency.
  • Regional performance: North America $249M, Latin America $278M, EMEA $214M, Asia excluding India $101M, India $26M in Q2 2026.
  • Operational priorities advanced: initiatives to reduce debt, improve core competitiveness, manage post-patent transition for Rynaxypyr®, and accelerate new active ingredient growth.
  • Strategic transactions announced to generate proceeds (~$1 billion target) for debt reduction, including sale of India commercial business for $252M, a $200M licensing upfront payment for rimisoxafen, a $114M sale-leaseback of Newark property, and a $400M equity investment from Tessenderlo Group.
  • Working capital and cash generation: GAAP cash from operations of $363.0M in Q2 2026, driven in part by the $200M upfront licensing payment; free cash flow (non-GAAP) of $357.4M for the quarter.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.